Global Bevacizumab Market Size By Type (Avastin (bevacizumab), Mvasi (bevacizumab-awwb)), By Application (Cancer, Eye Diease), By Region, And Segment Forecasts, 2023 to 2032

The Global Bevacizumab Market was valued at USD 7.1 billion in 2023 and is projected to reach USD 12.9 billion by 2031, expanding at a CAGR of 7.7% during the forecast period of 2023–2031. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), plays a critical role in cancer treatment by inhibiting angiogenesis. Its widespread use in oncology—particularly for colorectal, lung, renal, glioblastoma, and cervical cancers—drives steady market growth. Increasing cancer prevalence, rising adoption of targeted therapies, and advancements in biosimilars are key contributors to the market expansion.

Drivers:

1. Rising Global Cancer Incidence:

With over 19 million new cancer cases reported globally in 2023, the demand for targeted therapies such as bevacizumab has surged. Its efficacy in slowing tumor growth by cutting off blood supply makes it a vital option in cancer management.

2. Growing Preference for Targeted Therapies:

Targeted biologics like bevacizumab offer improved outcomes with fewer side effects compared to traditional chemotherapy, accelerating their adoption across oncology centers and hospitals.

3. Expanding Approvals and Indications:

Regulatory approvals for new indications of bevacizumab and its biosimilars, including use in ophthalmologic conditions and additional cancer types, are broadening its market reach.

Restraints:

1. High Treatment Costs:

Bevacizumab remains a costly therapy, which can limit access in developing regions and pose financial burdens even in advanced economies.

2. Patent Expiry and Biosimilar Competition:

While biosimilars promote market access, they also reduce the profit margins of branded formulations, creating competitive pressure.

Opportunity:

1. Proliferation of Biosimilars in Emerging Markets:

The launch of cost-effective bevacizumab biosimilars is opening doors in price-sensitive regions such as Asia-Pacific and Latin America, driving volume-based growth.

2. Expansion into Non-Oncology Applications:

Bevacizumab's use in ophthalmology, particularly for off-label treatment of age-related macular degeneration (AMD), presents a promising revenue avenue.

Market by System Type Insights:

Based on system type, the Original Biologics segment held the largest share in 2023 due to brand recognition and established efficacy. However, the Biosimilars segment is expected to witness the fastest growth through 2031, driven by cost advantages and broader market penetration, especially post-patent expiration of key branded versions.

Market by End-Use Insights:

By end use, Hospitals accounted for the largest market share in 2023, as these institutions primarily administer bevacizumab infusions under strict medical supervision. The Oncology Specialty Clinics segment is projected to grow rapidly, supported by increasing outpatient chemotherapy setups and favorable reimbursement environments.

Market by Regional Insights:

North America dominated the global bevacizumab market in 2023, led by high cancer incidence, favorable insurance coverage, and the early adoption of biosimilars. Meanwhile, Asia-Pacific is poised to register the highest CAGR during the forecast period, with countries like India, China, and South Korea boosting biosimilar production, regulatory approvals, and accessibility.

Competitive Scenario:

Key players operating in the global bevacizumab market include F. Hoffmann-La Roche Ltd (Avastin), Amgen Inc., Pfizer Inc., Biocon Biologics Ltd., Mylan N.V., and Samsung Bioepis Co., Ltd. These companies are actively engaged in biosimilar launches, strategic collaborations, and clinical trials to enhance product availability and affordability. Notable developments include:

In 2023, Biocon Biologics gained FDA approval for its bevacizumab biosimilar, expanding its oncology portfolio in the U.S. market.

Amgen partnered with local distributors in Asia in 2024 to improve biosimilar penetration in underserved cancer care markets.

Roche launched a personalized oncology support initiative in 2022 to maintain brand dominance amidst biosimilar competition.

Scope of Work – Global Bevacizumab Market

Report Metric Details

Market Size (2023) USD 7.1 billion

Projected Market Size (2031) USD 12.9 billion

CAGR (2023–2031) 7.7%

Market Segments By System Type (Biologics, Biosimilars), End-use, Region

Growth Drivers Increasing cancer prevalence, rising adoption of targeted therapies

Opportunities Biosimilar expansion in emerging markets, ophthalmology applications

Key Market Developments:

May 2023: Roche launched a real-world evidence initiative for Avastin, aimed at strengthening clinician trust amid biosimilar growth.

July 2024: Pfizer expanded its oncology biosimilar portfolio in Latin America, including bevacizumab, to address regional affordability gaps.

February 2025: Samsung Bioepis announced regulatory approval of its bevacizumab biosimilar in the EU, supporting its global expansion strategy.

FAQs:

1. What is the current market size of the Global Bevacizumab Market?

The market was valued at USD 7.1 billion in 2023.

2. What is the major growth driver of the Global Bevacizumab Market?

The rising global prevalence of cancer and increasing adoption of targeted therapies are the key growth drivers.

3. Which is the largest region during the forecast period in the Global Bevacizumab Market?

North America holds the largest market share due to its advanced healthcare infrastructure and early biosimilar adoption.

4. Which segment accounted for the largest market share in the Global Bevacizumab Market?

The Original Biologics segment accounted for the largest share in 2023, while Biosimilars are gaining traction rapidly.

5. Who are the key market players in the Global Bevacizumab Market?

Key players include F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Biocon Biologics Ltd., and Samsung Bioepis Co., Ltd.